Ionis Pharmaceuticals Inc - Asset Resilience Ratio
Ionis Pharmaceuticals Inc (IONS) has an Asset Resilience Ratio of 62.70% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Also explore how large is Ionis Pharmaceuticals Inc's balance sheet for the complete picture of this company's asset base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1999–2024)
This chart shows how Ionis Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. See IONS net asset quality score to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Ionis Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see IONS stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.90 Billion | 62.7% |
| Total Liquid Assets | $1.90 Billion | 62.70% |
Asset Resilience Insights
- Very High Liquidity: Ionis Pharmaceuticals Inc maintains exceptional liquid asset reserves at 62.70% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Ionis Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Ionis Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Royalty Pharma Plc
NASDAQ:RPRX |
Biotechnology | 0.11% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
|
Hyundai Bioscience Co. Ltd
KQ:048410 |
Biotechnology | 13.57% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 82.25% |
|
Lifecome Biochemistry Co Ltd
SHE:002868 |
Biotechnology | 4.69% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
Annual Asset Resilience Ratio for Ionis Pharmaceuticals Inc (1999–2024)
The table below shows the annual Asset Resilience Ratio data for Ionis Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 68.44% | $2.06 Billion | $3.00 Billion | +3.82pp |
| 2023-12-31 | 64.61% | $1.93 Billion | $2.99 Billion | -3.31pp |
| 2022-12-31 | 67.92% | $1.72 Billion | $2.53 Billion | +20.22pp |
| 2021-12-31 | 47.69% | $1.25 Billion | $2.61 Billion | -14.85pp |
| 2020-12-31 | 62.54% | $1.49 Billion | $2.39 Billion | +6.36pp |
| 2019-12-31 | 56.18% | $1.82 Billion | $3.23 Billion | -11.49pp |
| 2018-12-31 | 67.67% | $1.81 Billion | $2.67 Billion | +0.11pp |
| 2017-12-31 | 67.55% | $893.09 Million | $1.32 Billion | +67.29pp |
| 2016-12-31 | 0.26% | $2.41 Million | $912.47 Million | -2.33pp |
| 2015-12-31 | 2.59% | $24.79 Million | $956.11 Million | -5.97pp |
| 2014-12-31 | 8.57% | $81.88 Million | $955.81 Million | +2.42pp |
| 2013-12-31 | 6.15% | $52.10 Million | $847.16 Million | -0.01pp |
| 2012-12-31 | 6.16% | $33.62 Million | $545.69 Million | -51.21pp |
| 2011-12-31 | 57.37% | $278.19 Million | $484.89 Million | -15.71pp |
| 2010-12-31 | 73.08% | $402.30 Million | $550.48 Million | +1.71pp |
| 2009-12-31 | 71.37% | $469.06 Million | $657.18 Million | +23.81pp |
| 2008-12-31 | 47.56% | $273.08 Million | $574.15 Million | +26.27pp |
| 2007-12-31 | 21.29% | $55.10 Million | $258.86 Million | -9.51pp |
| 2006-12-31 | 30.80% | $78.82 Million | $255.91 Million | -23.74pp |
| 2005-12-31 | 54.54% | $90.74 Million | $166.37 Million | +17.77pp |
| 2004-12-31 | 36.77% | $76.63 Million | $208.43 Million | -17.69pp |
| 2003-12-31 | 54.45% | $182.39 Million | $334.94 Million | +11.71pp |
| 2002-12-31 | 42.74% | $187.50 Million | $438.68 Million | -1.62pp |
| 2001-12-31 | 44.36% | $185.01 Million | $417.06 Million | -3.47pp |
| 2000-12-31 | 47.83% | $87.65 Million | $183.26 Million | +30.85pp |
| 1999-12-31 | 16.97% | $17.50 Million | $103.11 Million | -- |
About Ionis Pharmaceuticals Inc
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pe… Read more